Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Job's Syndrome With Lupus-like Disease and/or Atopic Dermatitis
NCT07262983Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2026
- Primary completion
- May 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of baricitinib in hyperimmunoglobulin E syndrome (HIES), systemic lupus erythematosus (SLE) and atopic dermatitis (AD), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Adverse Events at 180 days. Started Nov 2026; status: recruiting.
02
Drugs
baricitinib
03
Conditions
hyperimmunoglobulin E syndrome (HIES)systemic lupus erythematosus (SLE)atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07262983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07262983.